Subscribe To
Repare therapeutics reveals early efficacy data from lead program in solid tumor setting
Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy ...
October 11, 2021, 6:21 am
Repare therapeutics reveals early efficacy data from lead program in solid tumor setting
Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy ...
October 11, 2021, 6:21 am
Repare therapeutics reveals early efficacy data from lead program in solid tumor setting
Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy ...
October 11, 2021, 6:21 am
Repare therapeutics presents preliminary phase 1 monotherapy clinical data from the ongoing first-in-human phase 1/2 tresr study of rp-3500 in solid tumors at aacr-nci-eortc international conference o
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 8, 2021, 3:10 pm
Repare therapeutics presents preliminary phase 1 monotherapy clinical data from the ongoing first-in-human phase 1/2 tresr study of rp-3500 in solid tumors at aacr-nci-eortc international conference o
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 8, 2021, 3:10 pm
Repare therapeutics presents preliminary phase 1 monotherapy clinical data from the ongoing first-in-human phase 1/2 tresr study of rp-3500 in solid tumors at aacr-nci-eortc international conference o
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 8, 2021, 3:10 pm
Repare therapeutics issues statement regarding inadvertent issuance of phase 1/2 tresr rp-3500 clinical trial abstract by the aacr-nci-eortc virtual international conference
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 7, 2021, 5:08 pm
Repare therapeutics issues statement regarding inadvertent issuance of phase 1/2 tresr rp-3500 clinical trial abstract by the aacr-nci-eortc virtual international conference
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 7, 2021, 5:08 pm
Repare therapeutics issues statement regarding inadvertent issuance of phase 1/2 tresr rp-3500 clinical trial abstract by the aacr-nci-eortc virtual international conference
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 7, 2021, 5:08 pm
Bicycle therapeutics stock falls after interim data of toxin conjugates in ovarian cancer trial
Bicycle Therapeutics plc (NASDAQ: BCYC) has reported interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose-escala...
October 7, 2021, 3:29 pm
Bicycle therapeutics stock falls after interim data of toxin conjugates in ovarian cancer trial
Bicycle Therapeutics plc (NASDAQ: BCYC) has reported interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose-escala...
October 7, 2021, 3:29 pm
Bicycle therapeutics stock falls after interim data of toxin conjugates in ovarian cancer trial
Bicycle Therapeutics plc (NASDAQ: BCYC) has reported interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose-escala...
October 7, 2021, 3:29 pm